Different expression of Bcl-2 in diffuse and intestinal type stomach carcinomas

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 825-828

  Klein, Rüdiger ^a   Vollmers, H Peter ^a   Müller Hermelink, Hans Konrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

apoptosis; Bcl 2 protein; neoplasm staging; proto oncogenes; stomach neoplasm

Indexed keywords

GENE PRODUCT; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; STOMACH CARCINOMA;

EID: 0029787341     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.5.825     Document Type: Article

References (31)

1. Parkin DM, Läära E and Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41: 184-197, 1988.
2. Rotterdam H: Carcinoma of the stomach. In: Pathology of the Stomach and the Duodenum. Rotterdam H and Enterlin HT (eds). Springer, Berlin, pp142-204, 1989.
3. Watanabe H, Jass JR and Sobin LH: Histological typing of oesophageal and gastric tumors. Springer, Berlin, pp20-26, 1990.
4. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. APMIS 64: 31-49, 1965.
5. Ming SC: Gastric carcinoma. A pathobiological classification. Cancer 39: 2475-2485, 1977.
6. Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 4: 413-420, 1992.
7. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 52: 6735-6740, 1992.
8. Vollmers HP, Dämmrich J, Ribbert H, Grassel S, Debus S, Heesemann J and Müller-Hennelink HK: Human monclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach carcinoma cells in vitro. Cancer 74: 1525-1532, 1994.
9. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI and Blaser MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325: 1132-1136, 1991.
10. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097-1099, 1984.
11. Tsujimoto Y, Cossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
12. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
13. Chen-Levy Z, Nourse J and Cleary ML: The bcl-2 candidate proto-oncogene product is a 24 kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9: 701-710, 1989.
14. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
15. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the Bcl-2 oncoprotein: resistance in the nuclear envelope, endoplasmatic reticulum and outer mitochondrial membranes. Cancer Res 53: 4701-4714, 1993.
16. Vaux DL, Cory S and Adams JM: bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
17. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP and Korsmeyer SJ: Deregulated bcl-2 gene expression selectively prolongs survival of growth-factor deprived hemopoietic cell lines. J Immunol 144: 3602-3610, 1990.
18. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
19. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM and Campbell ML: Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
20. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329: 690-694, 1993.
21. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M and Viale G: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424: 47-51, 1994.
22. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R and Pierotti MA: Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 172: 337-342, 1994.
23. Spiessel B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH and Wagner G: UICC TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumors. 3rd edition, 2nd revision. Springer, Berlin, pp71-81, 1992.
24. Vollmers HP, Stulle K, Dämmrich J, Pfaff M, Papadopoulos T, Betz C, Saal K and Müller-Hermelink HK: Characterization of four new gastric cancer cell lines. Virchows Arch (B) 63: 335-343, 1993.
25. LeBrunn DP, Kamel OW, Cleary ML, Dorfman RF and Warnke RA: Follicular lymphomas of the gastrointestinal tract. Am J Pathol 140: 1327-1335, 1992.
26. Lauwers GY, Scott GV and Hendricks J: Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 73: 2900-2904, 1994.
27. Bronner MP, Culin C, Reed JC and Furth EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146: 20-26, 1995.
28. Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
29. Lauwers GY, Scott GV and Karpeh MS: Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 75: 2209-2213, 1995.
30. Alsabeh R, Wilson CS, Ahn CW, Vasef MA and Battifora H: Expression of bcl-2 by breast cancer: a possible diagnostic application. Modern Pathol 9: 439-444, 1996.
31. Bhargava V, Kell DL, Van de Rijn M and Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145: 535-540, 1994.